Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)
This study will include patients with a short-axis diameter of a pelvic or para-aortic LN ≥2 cm or ≥3 LNs with a short-axis diameter ≥1 cm and for whom CCRT is planned. The treatment arms will be randomly allocated in a 1:1 ratio to either receive CCRT (control arm) or undergo surgical debulking of bulky or multiple LNs before CCRT (experimental arm). CCRT consists of extended-field external beam radiotherapy/pelvic radiotherapy, brachytherapy and LN boost, and weekly chemotherapy with cisplatin (40 mg/m²), 4-6 times administered intravenously. The primary endpoint will be 3-year progression-free survival rate. The ...
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Bo Seong Yun Kwang-Beom Lee Keun Ho Lee Ha Kyun Chang Joo-Young Kim Myong Cheol Lim Chel Hun Choi Hanbyoul Cho Dae-Yeon Kim Yun Hwan Kim Joong Sub Choi Chae Hyeong Lee Jae-Weon Kim Sang Wun Kim Yong Bae Kim Chi-Heum Cho Dae Gy Hong Yong Jung Song Seob Jeo Source Type: research
Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
CONCLUSION: Tisotumab vedotin was unlikely cost-effective compared to chemotherapy for recurrent or metastatic cervical cancer patients at a willingness-to-pay threshold of $150,000/QALY from the perspective of a U.S. payer. Lowering the prices of tisotumab vedotin could potentially enhance its cost-effectiveness.PMID:38330381 | DOI:10.3802/jgo.2024.35.e58 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Gengwei Huo Wenjie Liu Peng Chen Source Type: research
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
J Gynecol Oncol. 2024 Jan 25. doi: 10.3802/jgo.2024.35.e66. Online ahead of print.ABSTRACTIn the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced,...
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Seung-Hyuk Shim Jung-Yun Lee Yoo-Young Lee Jeong-Yeol Park Yong Jae Lee Se Ik Kim Gwan Hee Han Eun Jung Yang Joseph J Noh Ga Won Yim Joo-Hyuk Son Nam Kyeong Kim Tae-Hyun Kim Tae-Wook Kong Youn Jin Choi Angela Cho Hyunji Lim Eunbi Jang Hyun Woong Cho Dong Source Type: research
A phase 1/2a, dose-escalation, safety, and preliminary efficacy study of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2
CONCLUSION: The safety of RKP00156 was proved with no serious AEs. Although the study did not show any significance in histologic regression and HPV clearance, our findings indicate that RKP00156 may have a possibility of short-term inhibitory effect on HPV replication in patients with higher viral loads.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02139267.PMID:38330377 | DOI:10.3802/jgo.2024.35.e52 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Hyun-Woong Cho Sohyeon Jeong Seung Hun Song Young Tae Kim Jae-Weon Kim Chi-Heum Cho Soo Young Hur Suk-Joon Chang Yong Man Kim Jae Kwan Lee Source Type: research
Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer
CONCLUSION: We found that HRRm can be a useful biomarker for predicting the effects of PARP inhibitors in treating ovarian cancer and that the PFI can also be useful in recurrent ovarian cancer.PMID:38330378 | DOI:10.3802/jgo.2024.35.e55 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Takahiro Nozaki Ikuko Sakamoto Keiko Kagami Kenji Amemiya Yosuke Hirotsu Hitoshi Mochizuki Masao Omata Source Type: research
HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010-2021): a retrospective study
CONCLUSION: HPV vaccination reduced the prevalence and duration of infection and kept the PS in an episomal form for both HPV16 and HPV18. The tendency of persistence VL to be higher than clearance in the unvaccinated group implies that the vaccine's effect of reducing VL in HPV16 may lower the risk of progression to cervical cancer by shortening the infection duration.PMID:38330379 | DOI:10.3802/jgo.2024.35.e56 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Yoo Jin Na Oeuk Jeong Jaehyun Seong JeongGyu Lee So Young Lee Sooyoung Hur Sangmi Ryou Source Type: research
Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)
This study will include patients with a short-axis diameter of a pelvic or para-aortic LN ≥2 cm or ≥3 LNs with a short-axis diameter ≥1 cm and for whom CCRT is planned. The treatment arms will be randomly allocated in a 1:1 ratio to either receive CCRT (control arm) or undergo surgical debulking of bulky or multiple LNs before CCRT (experimental arm). CCRT consists of extended-field external beam radiotherapy/pelvic radiotherapy, brachytherapy and LN boost, and weekly chemotherapy with cisplatin (40 mg/m²), 4-6 times administered intravenously. The primary endpoint will be 3-year progression-free survival rate. The ...
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Bo Seong Yun Kwang-Beom Lee Keun Ho Lee Ha Kyun Chang Joo-Young Kim Myong Cheol Lim Chel Hun Choi Hanbyoul Cho Dae-Yeon Kim Yun Hwan Kim Joong Sub Choi Chae Hyeong Lee Jae-Weon Kim Sang Wun Kim Yong Bae Kim Chi-Heum Cho Dae Gy Hong Yong Jung Song Seob Jeo Source Type: research
Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
CONCLUSION: Tisotumab vedotin was unlikely cost-effective compared to chemotherapy for recurrent or metastatic cervical cancer patients at a willingness-to-pay threshold of $150,000/QALY from the perspective of a U.S. payer. Lowering the prices of tisotumab vedotin could potentially enhance its cost-effectiveness.PMID:38330381 | DOI:10.3802/jgo.2024.35.e58 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Gengwei Huo Wenjie Liu Peng Chen Source Type: research
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
J Gynecol Oncol. 2024 Jan 25. doi: 10.3802/jgo.2024.35.e66. Online ahead of print.ABSTRACTIn the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced,...
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Seung-Hyuk Shim Jung-Yun Lee Yoo-Young Lee Jeong-Yeol Park Yong Jae Lee Se Ik Kim Gwan Hee Han Eun Jung Yang Joseph J Noh Ga Won Yim Joo-Hyuk Son Nam Kyeong Kim Tae-Hyun Kim Tae-Wook Kong Youn Jin Choi Angela Cho Hyunji Lim Eunbi Jang Hyun Woong Cho Dong Source Type: research
A phase 1/2a, dose-escalation, safety, and preliminary efficacy study of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2
CONCLUSION: The safety of RKP00156 was proved with no serious AEs. Although the study did not show any significance in histologic regression and HPV clearance, our findings indicate that RKP00156 may have a possibility of short-term inhibitory effect on HPV replication in patients with higher viral loads.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02139267.PMID:38330377 | DOI:10.3802/jgo.2024.35.e52 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Hyun-Woong Cho Sohyeon Jeong Seung Hun Song Young Tae Kim Jae-Weon Kim Chi-Heum Cho Soo Young Hur Suk-Joon Chang Yong Man Kim Jae Kwan Lee Source Type: research
Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer
CONCLUSION: We found that HRRm can be a useful biomarker for predicting the effects of PARP inhibitors in treating ovarian cancer and that the PFI can also be useful in recurrent ovarian cancer.PMID:38330378 | DOI:10.3802/jgo.2024.35.e55 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Takahiro Nozaki Ikuko Sakamoto Keiko Kagami Kenji Amemiya Yosuke Hirotsu Hitoshi Mochizuki Masao Omata Source Type: research
HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010-2021): a retrospective study
CONCLUSION: HPV vaccination reduced the prevalence and duration of infection and kept the PS in an episomal form for both HPV16 and HPV18. The tendency of persistence VL to be higher than clearance in the unvaccinated group implies that the vaccine's effect of reducing VL in HPV16 may lower the risk of progression to cervical cancer by shortening the infection duration.PMID:38330379 | DOI:10.3802/jgo.2024.35.e56 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Yoo Jin Na Oeuk Jeong Jaehyun Seong JeongGyu Lee So Young Lee Sooyoung Hur Sangmi Ryou Source Type: research
Therapeutic effects of surgical debulking of metastatic lymph nodes in cervical cancer IIICr: a trial protocol for a phase III, multicenter, randomized controlled study (KGOG1047/DEBULK trial)
This study will include patients with a short-axis diameter of a pelvic or para-aortic LN ≥2 cm or ≥3 LNs with a short-axis diameter ≥1 cm and for whom CCRT is planned. The treatment arms will be randomly allocated in a 1:1 ratio to either receive CCRT (control arm) or undergo surgical debulking of bulky or multiple LNs before CCRT (experimental arm). CCRT consists of extended-field external beam radiotherapy/pelvic radiotherapy, brachytherapy and LN boost, and weekly chemotherapy with cisplatin (40 mg/m²), 4-6 times administered intravenously. The primary endpoint will be 3-year progression-free survival rate. The ...
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Bo Seong Yun Kwang-Beom Lee Keun Ho Lee Ha Kyun Chang Joo-Young Kim Myong Cheol Lim Chel Hun Choi Hanbyoul Cho Dae-Yeon Kim Yun Hwan Kim Joong Sub Choi Chae Hyeong Lee Jae-Weon Kim Sang Wun Kim Yong Bae Kim Chi-Heum Cho Dae Gy Hong Yong Jung Song Seob Jeo Source Type: research
Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
CONCLUSION: Tisotumab vedotin was unlikely cost-effective compared to chemotherapy for recurrent or metastatic cervical cancer patients at a willingness-to-pay threshold of $150,000/QALY from the perspective of a U.S. payer. Lowering the prices of tisotumab vedotin could potentially enhance its cost-effectiveness.PMID:38330381 | DOI:10.3802/jgo.2024.35.e58 (Source: Journal of Gynecologic Oncology)
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Gengwei Huo Wenjie Liu Peng Chen Source Type: research
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
J Gynecol Oncol. 2024 Jan 25. doi: 10.3802/jgo.2024.35.e66. Online ahead of print.ABSTRACTIn the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced,...
Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Seung-Hyuk Shim Jung-Yun Lee Yoo-Young Lee Jeong-Yeol Park Yong Jae Lee Se Ik Kim Gwan Hee Han Eun Jung Yang Joseph J Noh Ga Won Yim Joo-Hyuk Son Nam Kyeong Kim Tae-Hyun Kim Tae-Wook Kong Youn Jin Choi Angela Cho Hyunji Lim Eunbi Jang Hyun Woong Cho Dong Source Type: research
